

1

2 **Supplementary Figure 1. Clinical data for 23 diagnostic peripheral T-cell lymphoma not**
3 **otherwise specified (PTCL-NOS) cases followed long-term at MSKCC.** A) Breakdown of
4 front-line therapy. B) Overall survival from date of diagnosis and event-free survival from date
5 of front-line treatment initiation. C) Comparison of overall survival between cases with nodal vs.
6 extranodal presentation.

7

8 **Supplementary Figure 2. Effects on overall survival by functional groupings. A)**
9 **Distribution of mutations in three functional groups among 23 cases with long-term clinical**
10 **data available.** B) Overall survival for cases with and without mutations affecting histone
11 methylation (*MLL2*, *KDM6A*, or *MLL*), DNA methylation (*TET2*, *DNMT3A*, or *TET1*) or
12 signaling (*TNFAIP3*, *APC*, *CHD8*, *ZAP70*, *NF1*, *TNFRSF14*, or *TRAF3*).